Ketamine vs. Spravato: Which Is Right for You?
Understanding Fast-Acting Depression Treatments
For people with treatment-resistant depression, both ketamine infusions and Spravato (esketamine) nasal spray offer rapid relief — often within hours to days rather than the weeks required by traditional antidepressants. Understanding the differences between these two options can help patients and providers make informed decisions.
Ketamine Infusions
Intravenous (IV) ketamine is administered in a clinic setting over approximately 40 minutes. Because it is delivered directly into the bloodstream, the dosage can be precisely controlled. Ketamine infusions are not FDA-approved specifically for depression and are considered off-label, meaning insurance coverage is limited and patients often pay out of pocket.
Spravato (Esketamine)
Spravato is an FDA-approved nasal spray containing esketamine, a chemical cousin of ketamine. It is self-administered in a certified healthcare setting under medical supervision for two hours after each dose. Because of its FDA approval status, Spravato is more likely to be covered by insurance, making it more accessible for many patients.
Key Differences
The primary differences relate to delivery method, cost, and insurance coverage. Ketamine infusions may offer more flexibility in dosing, while Spravato provides a standardized FDA-approved protocol. Both require multiple sessions and ongoing maintenance treatment to sustain results.
Which Is Right for You?
The best option depends on your insurance coverage, medical history, and personal preferences. A consultation with a psychiatrist experienced in interventional treatments will help determine the most appropriate approach for your individual situation.
